Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 8/20 | 0.44 |
| ▸ | NPY1R | P25929 | 5/20 | 0.44 |
| ▸ | NPY2R | P49146 | 4/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31228648 | 0.96 | VIPR2 (0.43) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL29422990 | 0.96 | VIPR2 (0.43) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL30118959 | 0.90 | ENPEP (0.41) | NPY4RNPY1RNPY2RNPY5RENPEP | |
| SCHEMBL29406555 | 0.90 | VIPR2 (0.49) | BACE1CTSDENPEP | |
| SCHEMBL29500481 | 0.90 | VIPR2 (0.49) | BACE1CTSDENPEP | |
| SCHEMBL30456269 | 0.89 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RENPEP | |
| SCHEMBL30148448 | 0.89 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RENPEP | |
| SCHEMBL30456308 | 0.89 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RENPEP | |
| SCHEMBL30148464 | 0.89 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RENPEP | |
| SCHEMBL31107071 | 0.87 | NPY4R (0.44) | BACE1CTSDNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035430-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-12473339-B2 | Acylated glucagon analogues | ZEALAND PHARMA A/S (DK) | 2025-11-18 | — | — | US | disclosed |
| CN-111094331-B | Acylated oxyntomodulin peptide analogues | 东亚ST株式会社 | 2024-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035430-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCG, GCGR | BACE1 2697/4885CTSD 3997/4885NPY4R 17/4885 |
| US-12473339-B2 | Acylated glucagon analogues | GLP1R, GCGR, GIPR | BACE1 2498/4885CTSD 2943/4885NPY4R 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.